Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, announced that President and CEO Todd C. Brady will speak at the H.C. Wainwright Global Investment Conference. The fireside chat, featuring Vice President of Equity Research Matthew Caufield, will be available on demand starting 7:00 a.m. ET on May 24, 2022. Interested viewers can access the event through the Investors & Media section on Aldeyra's website, which will be archived for 90 days. Aldeyra's leading products include reproxalap and ADX-629, targeting immune-inflammation.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.

Dr. Brady’s conversation with Matthew Caufield, Vice President, Equity Research for H.C. Wainwright, will be available on demand beginning at 7:00 a.m. ET Tuesday, May 24, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005767/en/

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 857-383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is Aldeyra Therapeutics discussing at the H.C. Wainwright Global Investment Conference?

Aldeyra Therapeutics will have President Todd C. Brady participate in a fireside chat about their innovative therapies for immune-mediated diseases.

When is the Aldeyra Therapeutics fireside chat scheduled?

The fireside chat is available on demand starting at 7:00 a.m. ET on May 24, 2022.

How can I access the Aldeyra Therapeutics conference webcast?

You can view the webcast through the Investors & Media section on Aldeyra's website.

How long will the Aldeyra Therapeutics conference archive be available?

The conference archive will be available on Aldeyra's website for 90 days.

What are Aldeyra's lead product candidates mentioned in the press release?

Aldeyra's lead products are reproxalap and ADX-629, which target immune-mediated inflammation.